China Merchants Group led a series C round for the antibody drug developer that was also backed by fellow corporates Tigermed and Dawn.
China-based antibody drug developer Gmax Biopharm International has received $78m in a series C round led by diversified conglomerate China Merchants Group, DealStreetAsia has reported.
The round also featured clinical contract research organisation Tigermed, telecommunications firm Dawn, Parkland Medtech, Brill Capital, Cowin Capital and Ziyao Fund.
Founded in 2010, Gmax is developing antibody and bi-body drugs that will be used to treat cancer, cardiovascular diseases and metabolic disorders.
The company’s pipeline is intended to target G-protein coupled receptors (GPCRs), a…
